This article is more than 5 years old. Information may no longer be current.
City of Hope names medical director for clinical research operations
Click Here to Manage Email Alerts
Karen Reckamp, MD, MS, a medical oncologist and lung cancer researcher, has been named medical director for clinical research operations at City of Hope.
In this newly created position, Reckamp will expand her current role as chair of the cancer protocol review and monitoring committee, in which she has supported and shaped the regulatory, operational and scientific directives of the clinical research mission of City of Hope.
Karen Reckamp
As medical director, she will serve as medical adviser for clinical research operations, medical director of the clinical trials unit and coordinating liaison for pharmaceutical contracts. She will also share responsibility for the review and selection of clinical trials within City of Hope.
“Karen has shown remarkable leadership as City of Hope moves to launch a new era of scientific research and life-saving clinical trials,” Larry W. Kwak, MD, PhD, associate director for developmental therapeutics and translational research at City of Hope and director of the Toni Stephenson Lymphoma Center, said in a press release. “Her deep knowledge of the complex regulatory and operational aspects of City of Hope’s clinical trials has been, and will continue to be, invaluable as we rapidly turn breakthrough research into new treatments and cures.”
Reckamp also is co-chair of the institution’s lung cancer and thoracic oncology program. She joined City of Hope in 2007 as assistant professor of medicine in the department of medical oncology and therapeutics. In 2012, she became associate professor in the department of medical oncology and therapeutics research and co-director of the lung cancer and thoracic oncology program at City of Hope.